Isotretinoin
- Generic Name
- Isotretinoin
- Brand Names
- Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 4759-48-2
- Unique Ingredient Identifier
- EH28UP18IF
- Background
Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-cont...
- Indication
Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.
- Associated Conditions
- Acne conglobata, Neuroblastoma (NB), Rosacea, Sezary Syndrome, Early Mycosis Fungoides (MF), Refractory Acne vulgaris, Severe Recalcitrant nodular acne
- Associated Therapies
- -
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 18
- Registration Number
- NCT01020539
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Cipher Pharmaceuticals Inc.
- Target Recruit Count
- 925
- Registration Number
- NCT00975143
- Locations
- 🇨🇦
UltraNova Skincare, Barrie, Ontario, Canada
🇨🇦Institute of Cosmetic and Laser Surgery, Oakville, Ontario, Canada
🇨🇦Dermatrials Research, Hamilton, Ontario, Canada
Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
- Conditions
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 75
- Registration Number
- NCT00939965
- Locations
- 🇬🇧
University of Newcastle-Upon-Tyne Northern Institute for Cancer Research, Newcastle-Upon-Tyne, England, United Kingdom
🇬🇧Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧Royal Marsden - Surrey, Sutton, England, United Kingdom
Isotretinoin in Papular-Pustular Rosacea
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2009-11-17
- Lead Sponsor
- Laboratoires Bailleul-Biorga
- Target Recruit Count
- 156
- Registration Number
- NCT00882531
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00867178
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT00808899
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideRadiation: External Beam Radiation TherapyBiological: FilgrastimDrug: IsotretinoinOther: Laboratory Biomarker AnalysisDrug: MelphalanProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyDrug: Topotecan HydrochlorideDrug: ThiotepaDrug: Vincristine Sulfate Liposome
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 665
- Registration Number
- NCT00567567
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
- Conditions
- Interventions
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00555399
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2015-07-16
- Target Recruit Count
- 360
- Registration Number
- NCT00526318
- Locations
- 🇩🇪
Klinikum Augsburg, Augsburg, Germany
🇩🇪Evangelisches Krankenhauus Bielfeld, Biefeld, Germany
🇩🇪Klinikum Duisburg, Duisburg, Germany
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 464
- Registration Number
- NCT00499616
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.